Laurence Lodé, Audrey Ménard, Laurent Flet, Steven Richebourg, Marion Loirat, Marion Eveillard, Yannick Le Bris, Catherine Godon, Olivier Theisen, Anne-Laure Gagez, Guillaume Cartron, Thérèse Commes-Maerten, Bruno Villemagne, Odile Luycx, Pascal Godmer, Catherine Pellat-Deceunynck, Thierry Soussi, Marie C. Béné, Jacques Delaunay, Pierre Peterlin. Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. Haematologica 2018;103(4):e143-e146; https://doi.org/10.3324/haematol.2017.181404.